116 related articles for article (PubMed ID: 38552844)
1. Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Solh M; Bashey A; Zhang X; Holland HK; Bachier-Rdriguez L; Morris LE; Solomon SR
Transplant Cell Ther; 2024 Jun; 30(6):607.e1-607.e8. PubMed ID: 38552844
[TBL] [Abstract][Full Text] [Related]
2. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.
Bashey A; Zhang X; Jackson K; Brown S; Ridgeway M; Solh M; Morris LE; Holland HK; Solomon SR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):125-33. PubMed ID: 26359881
[TBL] [Abstract][Full Text] [Related]
4. Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.
Solomon SR; Aubrey MT; Bachier-Rodriguez L; Solh MM; Jackson KC; Zhang X; Roark CL; Holland HK; Morris LE; Bashey A
Transplant Cell Ther; 2024 Jun; 30(6):608.e1-608.e10. PubMed ID: 38561140
[TBL] [Abstract][Full Text] [Related]
5. Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.
Solomon SR; Zhang X; Holland HK; Morris LE; Solh M; Bashey A
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1237-1242. PubMed ID: 29378303
[TBL] [Abstract][Full Text] [Related]
6. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
7. Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.
Solomon SR; Aubrey MT; Zhang X; Jackson KC; Roark CL; Freed BM; Morris LE; Holland HK; Solh MM; Bashey A
Transplant Cell Ther; 2022 Sep; 28(9):601.e1-601.e8. PubMed ID: 35788088
[TBL] [Abstract][Full Text] [Related]
8. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
10. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis.
Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Gouill SL; Béné MC; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):861.e1-861.e7. PubMed ID: 34245928
[TBL] [Abstract][Full Text] [Related]
11. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
[TBL] [Abstract][Full Text] [Related]
12. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Mehta RS; Saliba RM; Ghanem S; Alousi AM; Rondon G; Anderlini P; Al-Atrash G; Bashir Q; Hosing CM; Im JS; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Saini N; Srour SA; Champlin RE; Rezvani K; Shpall EJ
Transplant Cell Ther; 2022 Jul; 28(7):395.e1-395.e11. PubMed ID: 35513252
[TBL] [Abstract][Full Text] [Related]
14. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
16. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
[TBL] [Abstract][Full Text] [Related]
17. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Gooptu M; Romee R; St Martin A; Arora M; Al Malki M; Antin JH; Bredeson CN; Brunstein CG; Chhabra S; Fuchs EJ; Ghosh N; Grunwald MR; Kanakry CG; Kekre N; McGuirk JP; McNiece IK; Mehta RS; Mielcarek M; Milano F; Modi D; Reshef R; Solomon SR; Schroeder MA; Waller EK; Inamoto Y; Soiffer RJ; Eapen M
Blood; 2021 Jul; 138(3):273-282. PubMed ID: 34292325
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
20. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
